NO991342L - Anvendelse av fumarsyrederivater ved behandling av autoimmune sykdommer - Google Patents

Anvendelse av fumarsyrederivater ved behandling av autoimmune sykdommer

Info

Publication number
NO991342L
NO991342L NO991342A NO991342A NO991342L NO 991342 L NO991342 L NO 991342L NO 991342 A NO991342 A NO 991342A NO 991342 A NO991342 A NO 991342A NO 991342 L NO991342 L NO 991342L
Authority
NO
Norway
Prior art keywords
fumaric acid
treatment
acid derivatives
autoimmune diseases
administration
Prior art date
Application number
NO991342A
Other languages
English (en)
Other versions
NO326815B1 (no
NO991342D0 (no
Inventor
Kumar Rajendra Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of NO991342D0 publication Critical patent/NO991342D0/no
Publication of NO991342L publication Critical patent/NO991342L/no
Publication of NO326815B1 publication Critical patent/NO326815B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO991342A 1997-05-20 1999-03-19 Anvendelse av fumarsyrederivater ved behandling av autoimmune sykdommer NO326815B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19721099A DE19721099C2 (de) 1997-05-20 1997-05-20 Verwendung von Fumarsäurederivaten
PCT/EP1998/001894 WO1998052549A2 (de) 1997-05-20 1998-04-01 Verwendung von fumarsäurederivaten

Publications (3)

Publication Number Publication Date
NO991342D0 NO991342D0 (no) 1999-03-19
NO991342L true NO991342L (no) 1999-11-16
NO326815B1 NO326815B1 (no) 2009-02-23

Family

ID=7829995

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991342A NO326815B1 (no) 1997-05-20 1999-03-19 Anvendelse av fumarsyrederivater ved behandling av autoimmune sykdommer

Country Status (24)

Country Link
US (1) US6436992B1 (no)
EP (1) EP0980242B1 (no)
JP (1) JP3881038B2 (no)
CN (1) CN1153569C (no)
AT (1) ATE232093T1 (no)
AU (1) AU730441B2 (no)
BG (1) BG64613B1 (no)
BR (1) BR9809655A (no)
CA (1) CA2248955C (no)
CZ (1) CZ299960B6 (no)
DE (2) DE19721099C2 (no)
DK (1) DK0980242T3 (no)
EE (1) EE03999B1 (no)
ES (1) ES2190588T3 (no)
HU (1) HU227697B1 (no)
IL (1) IL132819A (no)
NO (1) NO326815B1 (no)
NZ (1) NZ501755A (no)
PL (1) PL190864B1 (no)
RS (1) RS49654B (no)
RU (1) RU2197963C2 (no)
SK (1) SK285897B6 (no)
TR (1) TR199902587T2 (no)
WO (1) WO1998052549A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
AU2002219236B2 (en) * 2001-01-12 2006-02-09 Biogen International Gmbh Fumaric acid amides
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
SI2801354T1 (sl) * 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2007148744A1 (ja) * 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
PT2139467T (pt) * 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
KR101699912B1 (ko) 2009-01-09 2017-01-25 포워드 파마 에이/에스 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
EP3466420A1 (en) * 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
PT2533634E (pt) 2010-02-12 2015-12-28 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
EP2713724A4 (en) * 2011-05-26 2015-03-11 Biogen Idec Inc METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT
JP6385273B6 (ja) 2011-06-08 2023-12-15 バイオジェン・エムエイ・インコーポレイテッド 高純度結晶性ジメチルフマラートの調製方法
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN113244185A (zh) 2012-02-07 2021-08-13 比奥根玛公司 含有富马酸二甲酯的药物组合物
JP5918395B2 (ja) 2012-02-07 2016-05-18 ゼノポート，インコーポレイティド モルホリノアルキルフマレート化合物、医薬組成物及び使用方法
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
JP2015527372A (ja) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
JP6506174B2 (ja) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド 重水素置換されたフマル酸誘導体
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
CN105452213B (zh) 2013-03-14 2017-09-22 阿尔克梅斯制药爱尔兰有限公司 富马酸酯前体药物及其在治疗多种疾病中的应用
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN104415026A (zh) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 氘代富马酸衍生物在治疗多发性硬化症中的应用
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
CA2962916C (en) * 2014-10-08 2021-06-15 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2016090154A1 (en) 2014-12-04 2016-06-09 Biogen Ma Inc. Multiple sclerosis treatment regimen using dimethyl fumarate
WO2016126540A1 (en) * 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
AU2015381240A1 (en) 2015-02-08 2017-07-06 Alkermes Pharma Ireland Limited Monomethylfumarate prodrug compositions
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
JP2019510743A (ja) * 2016-02-12 2019-04-18 ウニヴェルズィテート チューリッヒ 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート（ｄｍｆ）
CN107973714A (zh) * 2017-12-26 2018-05-01 荆门医药工业技术研究院 一种富马酸单乙酯盐类的制备方法
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
WO2022132978A1 (en) * 2020-12-18 2022-06-23 Upsher-Smith Laboratories, Llc Modified release solid oral dosage form for once daily administration of monomethyl fumarate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US4346118A (en) * 1980-05-02 1982-08-24 University Of Delaware Antimicrobial agents added to animal feeds
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
DE3531597A1 (de) * 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4768439A (en) * 1987-10-23 1988-09-06 Singer Stewart M Flare composition and flare comprising said composition
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH06345644A (ja) * 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
JPH07278187A (ja) * 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) * 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) * 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물

Also Published As

Publication number Publication date
JP3881038B2 (ja) 2007-02-14
DE19721099C2 (de) 1999-12-02
EP0980242B1 (de) 2003-02-05
BR9809655A (pt) 2000-07-11
HUP0001684A3 (en) 2001-09-28
SK41599A3 (en) 2000-12-11
RU2197963C2 (ru) 2003-02-10
AU7213698A (en) 1998-12-11
WO1998052549B1 (de) 1999-05-14
JP2000513023A (ja) 2000-10-03
WO1998052549A3 (de) 1999-04-08
EP0980242A2 (de) 2000-02-23
IL132819A0 (en) 2001-03-19
CA2248955C (en) 2001-08-14
CZ108099A3 (cs) 1999-08-11
HK1027512A1 (en) 2001-01-19
SK285897B6 (sk) 2007-10-04
DE19721099A1 (de) 1998-11-26
ES2190588T3 (es) 2003-08-01
EE9900535A (et) 2000-06-15
RS49654B (sr) 2007-09-21
YU57599A (sh) 2001-12-26
NO326815B1 (no) 2009-02-23
PL335381A1 (en) 2000-04-25
IL132819A (en) 2004-12-15
US6436992B1 (en) 2002-08-20
EE03999B1 (et) 2003-04-15
TR199902587T2 (xx) 2000-08-21
BG64613B1 (bg) 2005-09-30
WO1998052549A2 (de) 1998-11-26
ATE232093T1 (de) 2003-02-15
NO991342D0 (no) 1999-03-19
NZ501755A (en) 2001-07-27
CZ299960B6 (cs) 2009-01-07
HUP0001684A2 (hu) 2000-09-28
DK0980242T3 (da) 2003-04-14
DE59807122D1 (de) 2003-03-13
PL190864B1 (pl) 2006-02-28
HU227697B1 (en) 2011-12-28
CN1257426A (zh) 2000-06-21
CA2248955A1 (en) 1997-05-20
CN1153569C (zh) 2004-06-16
BG103335A (en) 2000-04-28
AU730441B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
NO991342D0 (no) Anvendelse av fumarsyrederivater ved behandling av autoimmune sykdommer
ATE221379T1 (de) Verfahren zur behandlung infektiöser respiratorischer erkrankungen
EE05025B1 (et) Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
DE69614174D1 (de) Verfahren zur Herstellung von optisch-aktiven Gamma-substituierte-Hydroxy-Buttersäure-Ester
DE69625906D1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69422064D1 (de) Verfahren zur Herstellung von optischaktiven 4-Halo-3-hydroxybuttersäure-Estern
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE69805846D1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
HUP9701540A1 (hu) A gasztrointesztinális keringést elősegítő gyógyászati készítmény
DE69327263D1 (de) Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose
DE69614375D1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE59300921D1 (de) Verfahren zur Herstellung von beta-Hydroxycarbonsäureestern.
NO923393L (no) Fremgangsmaate for inhibering av korrosjon i broenner som syrebehandle
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
FI935712L (fi) Menetelmä optisesti aktiivisten transglysidihappoestereiden entsyaattiseksi valmistamiseksi
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
DK0657431T3 (da) 4-Phenyl-3-substituerede 1,4-dihydropyridinestere med cerebral virkning.
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
ATE129636T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN INTERNATIONAL GMBH, CH

MM1K Lapsed by not paying the annual fees